Form 4: UroGen Pharma Director Stuart Holden Acquires 10,000 Stock Options
SEC Form 4 Filing
Director Stuart Holden acquired 10,000 stock options in UroGen Pharma Ltd. on August 6, 2024.
Summary
- On August 6, 2024, Stuart Holden, a director of UroGen Pharma Ltd., acquired 10,000 stock options.
- The exercise price of these options is $15.16.
- The options vest in equal quarterly installments over one year, contingent upon continuous service as a director.
- The options expire on August 6, 2034.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard regulatory filing indicating a director's stock option grant. It doesn't inherently suggest positive or negative implications for the company's performance.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, which is common for corporate insiders reporting changes in their beneficial ownership of company securities. It's a routine part of corporate governance and transparency.
Stakeholder Impact
- The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 08/06/2024 | Date of transaction: Stuart Holden acquired 10,000 stock options. |
| 08/06/2034 | Expiration date of the stock options. |
| 08/07/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.